Cardiac patient management at Guidant
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of the Contak Renewal 3 RF cardiac resynchronization therapy defibrillator and Zoom Latitude programmer will allow physicians to use remote monitoring to evaluate patients at three times the interrogation speed of the firm's previous programmer. Guidant plans to introduce the technology in the U.S. in Q4. Medtronic markets the CardioSight data access tool to cardiologists whose patients have been implanted with a defibrillator such as the InSync Sentry (1"The Gray Sheet" Aug. 22, 2005, In Brief)...
You may also be interested in...
Latitude for Guidant
FDA approves Guidant's Latitude communicator and secure data storage system, the final components of the Latitude patient monitoring system, the firm announces Sept. 19. The Latitude system, which also includes the Zoom Latitude programmer, allows patients with the Contak Renewal 3RF cardiac resynchronization therapy defibrillator (CRT-D) to wirelessly transmit data from their device to a secure Internet server at pre-specified times. Contak Renewal 3RF and Zoom Latitude were approved in August (1"The Gray Sheet" Aug. 29, 2005, In Brief)...
Cardiac monitoring for cardiologists
Medtronic will market its CardioSight data access tool to cardiologists treating heart failure patients who have one of several of the firm's resynchronization therapy defibrillators or ICD models, including the InSync Sentry CRT-D with OptiVol fluid monitoring system. Medtronic notes that CardioSight can detect dangerous fluid levels in the thoracic cavity up to two weeks prior to symptom development. The monitoring device enables non-implanting physicians to download 90 days of the patient's cardiac rhythm trends to improve treatment efficiency. Medtronic's CareLink network enables implanting physicians to remotely monitor patients with an ICD or pacemaker...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”